Epizyme (EPZM) Tops Q2 EPS by 10c

Epizyme (NASDAQ: EPZM) reported Q2 EPS of ($0.40), $0.10 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $9.5 million versus the consensus estimate of $7.59 million.

For earnings history and earnings-related data on Epizyme (EPZM) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)
• Enovix Corporation (ENVX) PT Lowered to $5 at BofA Securities